IL-27 in Vaccine-Elicited Cellular Immunity
IL-27 in Vaccine-Elicited Cellular Immunity
批准号:
8586517
负责人:
Ross M Kedl
金额:
$38.1万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-01-01 至 2017-11-30
关键词:
AdjuvantAffectAgonistAntigen PresentationAntigensAttenuatedAttenuated VaccinesBiologicalCD8B1 geneCellular ImmunityChronicCommunicable DiseasesDataDendritic CellsDendritic cell activationDependenceDependencyDevelopmentEquilibriumFundingGalactosylceramidesGoalsHIVHepatitis C virusImmuneImmune responseImmune systemImmunityImmunizationInfectionInfectious AgentInflammatoryInflammatory ResponseInterferonsInvestigationKnowledgeLifeListeria monocytogenesLiteratureMalariaMalignant NeoplasmsMediatingMemoryMetabolicMolecularMusPathway interactionsPatientsPatternPlayProcessProductionProteinsRoleSTAT1 geneSTAT3 geneShippingShipsSignal TransductionSiteSubunit VaccinesT cell responseT memory cellT-LymphocyteTNFRSF5 geneTestingTherapeuticTherapeutic InterventionToll-like receptorsVaccinationVaccine AdjuvantVaccinesVacciniaVaccinia virusVacciniumViralVirulenceattenuationbasecell typehuman FRAP1 proteinmTOR Signaling Pathwayneutralizing antibodynovelprogramsprophylacticpublic health relevancereceptorresponsetherapeutic vaccinevaccination strategyvaccine developmentvector
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Immunization with antigen in the presence of agonists for both a Toll Like Receptor (TLR) and CD40 (combined TLR/CD40 immunization) elicits a vigorous expansion of antigen-specific CD8+ T cells that is exponentially greater than the response elicited by either agonist alone. In the process of investigating our originally funded aims directed toward the role of type I IFN (IFN) in TLR/CD40 vaccination, we made the surprising discovery that the T cell response to any adjuvant containing a TLR-agonist is unexpectedly and completely dependent on IL-27. This is in sharp contrast to immunization with infectious vectors such as vaccinia or Listeria monocytogenes (LM) where the impact of IL-27 is negligible. Our data thus reveal a specific, obligate, and previously unappreciated role for IL-27 in non-infectious, subunit vaccine elicited cellular responses. Given the potency with which our combination adjuvant elicits cellular immunity, the obligate role of IL-27 in the cellular response
to combined innate/CD40 vaccination is reason enough for further examination. The additional and unexpected reality that essentially all molecularly defined vaccine adjuvants require the participation of IL-27 for eliciting cellular responses only adds to the importance of the studies proposed in this application. To fully understand the role of IL-27 in vaccine-elicited cellular immunity, we will clarify i) the sites and magnitude of IL-27 production, ii) the required pattern f IL-27R expression, iii) the role of IL-27 elicited STAT1 and STAT3 activation in DCs and T cells, and iv) the mechanisms by which vaccination and infectious processes diverge in their degree of IL-27 dependency.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
mRNA encoding of immune receptor-targeting antibodies for the augmentation of vaccine-elicited cellular immunity.
-
批准号:10508093
-
项目类别:
-
资助金额:$23.33万
-
财政年份:2022
-
负责人:Ross M Kedl
-
依托单位:
mRNA encoding of immune receptor-targeting antibodies for the augmentation of vaccine-elicited cellular immunity.
-
批准号:10662571
-
项目类别:
-
资助金额:$19.44万
-
财政年份:2022
-
负责人:Ross M Kedl
-
依托单位:
Exploring the heterogeneity of the vaccine-elicited T cell response by scRNAseq
-
批准号:10334559
-
项目类别:
-
资助金额:$19.44万
-
财政年份:2021
-
负责人:Ross M Kedl
-
依托单位:
Exploring the heterogeneity of the vaccine-elicited T cell response by scRNAseq
-
批准号:10218805
-
项目类别:
-
资助金额:$23.33万
-
财政年份:2021
-
负责人:Ross M Kedl
-
依托单位:
CD8 T cell and B cell collaboration following subunit vaccination
-
批准号:10450847
-
项目类别:
-
资助金额:$48.57万
-
财政年份:2020
-
负责人:Ross M Kedl
-
依托单位:
CD8 T cell and B cell collaboration following subunit vaccination
-
批准号:10662244
-
项目类别:
-
资助金额:$47.76万
-
财政年份:2020
-
负责人:Ross M Kedl
-
依托单位:
CD8 T cell and B cell collaboration following subunit vaccination
-
批准号:10055979
-
项目类别:
-
资助金额:$52.42万
-
财政年份:2020
-
负责人:Ross M Kedl
-
依托单位:
CD8 T cell and B cell collaboration following subunit vaccination
-
批准号:10242218
-
项目类别:
-
资助金额:$49.37万
-
财政年份:2020
-
负责人:Ross M Kedl
-
依托单位:
Molecular and cellular basis of Combined Adjuvant-Elicited Cellular Immunity
-
批准号:9312770
-
项目类别:
-
资助金额:$50.05万
-
财政年份:2016
-
负责人:Ross M Kedl
-
依托单位:
Molecular and cellular basis of Combined Adjuvant-Elicited Cellular Immunity
-
批准号:9197094
-
项目类别:
-
资助金额:$52.02万
-
财政年份:2016
-
负责人:Ross M Kedl
-
依托单位:
Lymphatic endothelial cell capture and maintenance of antigen
-
批准号:8895716
-
项目类别:
-
资助金额:$38.2万
-
财政年份:2015
-
负责人:Ross M Kedl
-
依托单位:
Virtual Memory T Cell Development and Responses In Vivo
-
批准号:9023407
-
项目类别:
-
资助金额:$35.02万
-
财政年份:2013
-
负责人:Ross M Kedl
-
依托单位:
Virtual Memory T Cell Development and Responses In Vivo
-
批准号:9222698
-
项目类别:
-
资助金额:$35.02万
-
财政年份:2013
-
负责人:Ross M Kedl
-
依托单位:
Virtual Memory T Cell Development and Responses In Vivo
-
批准号:8436534
-
项目类别:
-
资助金额:$35.6万
-
财政年份:2013
-
负责人:Ross M Kedl
-
依托单位:
Virtual Memory T Cell Development and Responses In Vivo
-
批准号:8634018
-
项目类别:
-
资助金额:$35.31万
-
财政年份:2013
-
负责人:Ross M Kedl
-
依托单位:
Antigen Persistence and Protective Immunity After Protein Vaccination
-
批准号:8502418
-
项目类别:
-
资助金额:$18.62万
-
财政年份:2012
-
负责人:Ross M Kedl
-
依托单位:
Antigen Persistence and Protective Immunity After Protein Vaccination
-
批准号:8386477
-
项目类别:
-
资助金额:$24.08万
-
财政年份:2012
-
负责人:Ross M Kedl
-
依托单位:
Combined TLR/CD40-Agonist Induced CD8+ T Cell Memory
-
批准号:8305322
-
项目类别:
-
资助金额:$38.68万
-
财政年份:2011
-
负责人:Ross M Kedl
-
依托单位:
Transcriptional regulation of vaccine-elicited and infection-elicited CD8+ T cell responses
-
批准号:10083688
-
项目类别:
-
资助金额:$38.88万
-
财政年份:2007
-
负责人:Ross M Kedl
-
依托单位:
IFNalphaBeta-Dependent and-Independent TLR/CD40 Synergy
-
批准号:7745527
-
项目类别:
-
资助金额:$37.39万
-
财政年份:2007
-
负责人:Ross M Kedl
-
依托单位:
海外基金